Compare Align Technology, Inc. (ALGN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Eli Lilly And Co — how do they compare? Align Technology, Inc. trades at $173.31 (market cap $12.29B), while Eli Lilly And Co trades at $1,218 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 87.9× Align Technology, Inc.'s market cap, and Eli Lilly And Co pays a 0.57% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | LLY | |
|---|---|---|
Market Cap | $12.29B | $1.08T |
Sector | Health | Health |
52-Week High | $197.51 | $1.24K |
52-Week Low | $124.88 | $639.43 |
Enterprise Value | $11.30B | $1.13T |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $176.04, up 1.37% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported record Q2 2026 revenue of $1.06 billion, driven by strong clear aligner volume growth. Analyst sentiment is positive, with 73% recommending buy, and institutional activity shows mixed positioning amid strategic initiatives like board changes and patent wins in China.
The outlook remains favorable due to solid fundamentals and international expansion, but risks include competitive pressures in digital dentistry and reliance on North American market stability. Earnings growth and margin improvements are key catalysts, though valuation multiples near five-year lows suggest potential upside if execution continues.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
